FDA warned Fukusui Shoji Ltd. that its fresh fish safety plan has serious gaps that make the fish unsafe under the law.
What happened
FDA inspected the seafood processing facility on February 8-9, 2023 and issued an FDA 483, a list of inspection observations. The company responded on April 7 and 8, 2023 with a written statement and a revised seafood safety plan (HACCP) for Group C fresh fish, but FDA said serious concerns remain. FDA found the plan does not cover Clostridium botulinum growth and toxin formation, has inadequate limits and monitoring for histamine (scombrotoxin) formation, and has corrective actions that do not address causes.
What FDA found
The revised seafood safety plan for Group C fresh fish did not identify the hazard of Clostridium botulinum growth and toxin formation, which FDA says is reasonably likely in the packaged fish shipped in an ice-filled cooler.
21 CFR 123.6(a) and (c)(1)The plan's critical limits at a control point were not adequate to control scombrotoxin (histamine) formation.
21 CFR 123.6(c)(3)The plan's monitoring procedures were not adequate to control scombrotoxin (histamine) formation, including no internal temperature limit and no clear timing for temperature checks.
21 CFR 123.6(c)(4)The corrective actions for Group C fresh fish at all listed control points did not address the cause of a deviation to prevent it from happening again.
21 CFR 123.7(b)
What FDA wants
FDA tells the company to respond in writing within 15 working days with specific corrections, including a revised seafood safety plan, five consecutive days of completed monitoring records for five production date codes, and any other information to show compliance. If corrections cannot be completed in 15 days, the company must explain the delay and state when it will finish.
Who should pay attention
- U.S. importers of Japanese fresh fish
- seafood processors that ship bagged fish in ice
- retailers and brands selling imported fresh fish
This is a summary. Read the original letter on fda.gov.